Letter: The risk-benefit balance of CRISPR-Cas screening systems in gene editing and targeted cancer therapy.

IF 6.1 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Journal of Translational Medicine Pub Date : 2024-11-07 DOI:10.1186/s12967-024-05834-z

Qiang Yi, Xinting Ouyang, Gangfeng Zhu, Jinghua Zhong

引用次数: 0

查看原文本刊更多论文

信：CRISPR-Cas 筛选系统在基因编辑和癌症靶向治疗中的风险收益平衡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Translational Medicine 医学-医学：研究与实验

CiteScore

10.00

自引率

1.40%

发文量

537

审稿时长

1 months

期刊介绍： The Journal of Translational Medicine is an open-access journal that publishes articles focusing on information derived from human experimentation to enhance communication between basic and clinical science. It covers all areas of translational medicine.